LANDEC

INVESTOR PRESENTATION OCTOBER 2020

IMPORTANT CAUTIONS REGARDING FORWARD-LOOKING STATEMENTS

Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

Potential risks and uncertainties include, without limitation, those mentioned in our most recent Annual Report on Form 10-K, as modified by any subsequent filings we make with the Securities and Exchange Commission (the "SEC") pursuant to the Securities Act of 1933 or the Exchange Act. Landec undertakes no obligation to update or revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this presentation.

This presentation contains summaries of financial and non-financial information that has been filed with the SEC pursuant to the Exchange Act. You should read this presentation in conjunction with our most recent Annual Report on Form 10-K and any subsequent Exchange Act filings.



STRONG BUSINESSES CREATING SHAREHOLDER VALUE

We demonstrate our commitment to shareholders by maximizing the value of our business portfolio, improving operating margins at Curation Foods, investing in growth to drive momentum at Lifecore while employing sustainable business practices to protect the planet for future generations.





LANDEC CONSOLIDATED FINANCIAL OVERVRIEW

	FY20 FINANCIAL METRICS	FY21 FINANCIAL GUIDANCE	Implied Growth
REVENUE	\$590mm	\$530mm - \$550mm	(10%) - (7%)
ADJUSTED EBITDA*	\$22mm	\$33mm - \$37mm	50% - 68%
ADJUSTED EBITDA MARGIN*	3.7%	6.2% - 6.7%	67% - 81%



^{*} Landec Consolidated Adjusted EBITDA also includes FY20 Corporate Expense of (\$2.8mm), incremental to segment level allocation

FY21 BUSINESS SEGMENT FINANCIAL GUIDANCE



	FY21	Implied Growth
Revenue	\$437mm- \$453mm	(13%) - (10%)
Adjusted EBITDA*	\$12mm- \$14mm	181% - 238%

DRIVERS

- Innovate break through high-margin products
- Pursuing operational excellence (Z.E.S.T.)
- Foster a culture of continuous improvement



	FY21	Implied Growth
Revenue	\$93mm- \$97mm	8% - 13%
Adjusted EBITDA*	\$22.5mm- \$24.5mm	12% - 22%

DRIVERS

- Build Business Development Pipeline
- Manage Current Capacity and Future Capacity needs
- Advance Product Commercialization

^{*} Landec Segment Adjusted EBITDA includes a majority of corporate allocation



LANDEC Q1 FINANCIAL RESULTS - KEY METRICS

	LANDEC		CURATION FOODS		LIFECORE	
	Q1 FY21	% CHANGE	Q1 FY21	% CHANGE	Q1 FY21	% CHANGE
LNDC CONSOLIDATED Q1 FY21 FINANCIALS						
Revenue	\$ 136mm	-2%	\$114mm	-10%	\$22mm	81%
Gross Profit Margin	12.10%	100 bps	10%	(10)bps	22.9%	200 bps
Adjusted EBITDA	\$3.1mm	890%	\$2.4mm	31%	\$1.5mm	N/M
Adjusted EBITDA %	2.30%	210 bps	2%	70 bps	6.6%	N/M

	LNDC Consolidated	OTHER	CURATION FOODS	LIFECORE
Q1 FY21 FINANCIAL METRICS - SEGMENT				
Restructuring and One Time Fees	\$10.6mm	\$2.1mm	\$8.5mm	
Corporate Overhead Allocation		(\$3.3mm)	\$1.9mm	\$ 1.4mm
Other Public Company Operating Loss- (after corporate overhead allocation)	\$2.8mm	\$2.8mm		
Capital Expenditures	\$4.6mm		\$1.9mm	\$2.7mm
Interest Expense, Net of Interest Income	\$3.1mm	\$1.7mm	\$1.4mm	
Income Tax (Benefit) Expense	(\$4.3mm)	(\$1.7mm)	(\$2.6mm)	\$0.04mm
Depreciation and Amortization	\$4.7mm		\$3.4mm	\$1.3mm





NEWS: ANNOUNCING CURATION FOODS

1992 BreatheWay patent

BreatheWay BreatheWay

1999

Eat Smart Acquisition (packaged fresh vegetables)



2012

GreenLine Acquisition



O Olive Oil & Vinegar Acquisition



2018

Yucatan Foods Acquisition









2002Eat Smart patented revolutionary "flip-and-serve" party tray



2013Launch of Sweet
Kale Salad



2017 Announced 100% clean label initiative



Today



Our mission is to provide 100% clean ingredient plant-based food to as many people as possible, in a way that respects people and protects the planet for future generations.

Launched in January 2019, Curation Foods is the corporate umbrella for our portfolio of natural food brands and patented packaging technology.



PROJECT SWIFT: PATHWAY TO PROFITABILITY




Simplify Win

Innovate

Focus

Transform



\$11.0M
Annualized Cost Savings

Network & Operational Optimization

Maximizing efficiency and productivity

- Centralization of Curation Foods offices into its Innovation Center headquarters in Santa Maria, CA,
- Continuous improvement in plant operations with lean manufacturing practices – Z.E.S.T

Focus on Strategic Assets

Simplify the business

- Completed asset sale and exited the lease salad dressing manufacturing facility - \$4.9mm
- Entered into a definitive agreement to sell Hanover manufacturing facility and related assets - \$8.7mm
- Streamline Eat Smart legacy vegetable and tray business

3 Organizational Redesign

Competitive structure

- Focus on strategic initiative
- Developing and elevating internal talent
- Reducing headcount

Project SWIFT is a value creation program will improve Curation Foods' operating cost structure, enhance profitability and strengthen the Company's balance sheet.



PROJECT SWIFT: SUSTAINABLE PROFITABILITY FISCAL 2021



Project SWIFT is providing a framework to transform Curation Foods into an agile and competitive company targeting significant operation improvements in steady-state organic growth and profitability on a run-rate basis by the end of fiscal 2021:









Financial targets include streamlining the Curation Foods legacy vegetable bag and tray business, right sizing the organization to competitive levels, meeting our aggressive cost-out targets.



CURATION FOODS MANUFACTURING OPERATIONAL SYSTEM



ZEST will empower our people to work in a different way, changing their mindset and behaviors leading to an acceleration of our performance across our operations. **ZEST** improved Avocado Products operations in FY20 and is rolling out to Curation Foods Network in Fiscal 2021

Zero breakdown, zero defects, zero recalls, accidents, zero pollution.

Empower employees to impact change. I operate. I maintain.
I own the outcomes.

TANDARDIZATION
Implementing the same practices across the network for efficiency.

The cornerstone of success and employee engagement.








We are a different kind of food company

Expanding from two brand to five natural food brands over the past two years, enhancing food offering with on-trend, plant-based products that contain 100% clean ingredients.



INNOVATING DIVERSIFIED HEALTH AND WELLNESS SOLUTIONS



FOCUS ON A SELECT PORTFOLIO OF NATURAL FOOD BRANDS





PACKAGED FRESH VEGETABLES

Discover delicious possibilities to Eat Smart



PREMIUM ARTISAN
OLIVE OILS & VINEGARS

Explore the surprising variety of flavors that makes everyday food taste extraordinary



AUTHENTIC FRESH GUACAMOLE

> Celebrate traditional, authentic Mexican taste



A FRESH TAKE ON GUACAMOLE

Experience fresh new flavors



SUPPLY CHAIN PACKAGING SOLUTION

Extends the shelf life of packaged fruits and vegetables naturally

PRODUCT TENETS:

100% Clean Ingredients | Delicious & Convenient | Plant-based & Healthy





The foundation of our company is end-user driven innovation.

Big ideas are often created by making small significant changes to existing products to deliver unmet needs.

Dr. Albert Bolles, PHDPresident & CEO, Landec Corporation
CEO, Curation Foods

1

Addressing customers/
consumers unmet needs

2

Delivering on trend plant-based foods

3

Expanding existing products' usage





Packaging Guacamole in squeeze container creates new usage occasion and keeps products fresher longer



RETAIL DISTRIBUTION

- Currently in 6,000 doors nationwide
- Yucatan Squeeze ACV 13.9%
- Cabo Fresh ACV 5.6%



MARKETING

- Geo-targeting based on store locations
- Focus on Retailer Specific Marketing Programs to drive in-store sales velocity and increase total category HH penetration



CATEGORY IMPACT

 Guacamole Squeeze is driving incremental growth Category



USAGE

Guacamole Squeeze expands the Guacamole Category from a standard "dip" to an everyday "condiment"



CONSUMER DRIVEN RESEARCH

- 71% of consumers would purchase 64% as a regular option for everyday meal and snacking
- 84% wish to keep guacamole fresh and green for 10 days
- 77% transforms guacamole usage from dip to a condiment



Convenience and packaging shift delivers high-margin product.





BreatheWay: Supply Chain Packaging Technology

Our patented packaging technology establishes a beneficial packaging atmosphere - adapting to changing produce respiration and temperature to extend freshness naturally

1995 PATENTED PACKAGING TECHNOLOGY



2019SUPPLY CHAIN PACKAGING SOLUTIONS



FUTURE

US & INTERNATIONAL BUSINESS DEVELOPEMENT PIPELINE



Keeps **individual** vegetable products in trays and bags fresh at retail

Keeps **pallets** at beneficial atmosphere during domestic supply chain transport resulting in more marketable fruit at retail.

Supply chain **packaging solutions** to transport perishable items by land and sea – testing berries, stone fruit, citrus, and flowers.



In market with Driscoll's raspberries delivered from North American distribution centers







Curation Foods is committed to delivering value to our shareholders while simultaneously working in a way that respects people and preserves the planet.



SOCIAL *People*







FOOD *Product*

All products have 100% clean ingredient label for all Curation Foods products

90% of all packaging is 100% curbside recyclable at Curation Foods




ENVIRONMENTAL *Planet*

50% of water being recycled system-wide at Curation Foods

38% of all energy comes from renewable sources at Curation Foods


SUSTAINABILITY PILLARS





LIFECORE: PROGRESS MADE POSSIBLE







Lifecore partners with leading pharmaceutical and biotech companies to create products that are difficult to formulate, filter, and/or fill.

We save our customers time and reduce barriers – so they can focus on creating innovations that change lives.

It's not what we make. It's what we make possible.

Leveraging over 35 years of experience to bring our customers' innovations to market



FAVORABLE TRENDS FUEL LONG-TERM DEMAND



Drug development
is on the rise

1

+5.2% CAGR*

(Pre-Clinical; Phase 1-3) 2008 - 2018

High propensity to outsource manufacturing among smalland mid-sized organizations

2

+74% of total approvals**

(Percentage of total NDA approvals outsourced by small- and mid-sized organizations) 2008 – 2018

Growing Injectable NDA approvals

3

45% of total approvals Growing 3X total market **

(Injectables) 2007 - 2017

Demand for specialized CDMO vial & syringe capacity

4

90-132
Estimated new approvals

of injectables to CDMOs

75-100M units*

incremental demand for vials & syringes



^{*} Informa, Pharma R&D Annual Review 2018

^{**} GlobalData PharmSource database; NDA approvals 2009-2018.

^{***} GlobalData PharmSource database

^{****} GlobalData PharmSource Report: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023



Lifecore Strategic Priorities



Build Business Development Pipeline

15 – 20 projects in various stages of the product lifecycle

2

Manage Capacity

Maximize Capacity for current customers and future growth generated from business development pipeline

3

Advance Product Commercialization

Target a minimum of **one regulatory product** approval annually

Currently have one product under review at the FDA






TWO PLATFORMS FOR LAUNCHING AND MANUFACTURING FUTURE MEDICAL PRODUCTS:

A leading supplier of pharmaceutical grade, sodium hyaluronate in ophthalmology, orthopedic and veterinary medicine A fully integrated Contract Development & Manufacturing Organization (CDMO) assisting companies to bring new, FDA-approved injectable therapies to market



REVENUE STREAMS




FY20

- Revenues: \$85.8mm
- Adjusted EBITDA: \$20.1mm





LIFECORE REVENUE AND CAPEX VS THEORETICAL CAPACITY







TRUSTED PRODUCER OF PREMIUM HYALURONIC ACID (HA)

	Type of HA	Quality	Uses & Types of Products	Barriers to Competition
Lifecore BIOMEDICAL	Pharmaceutical Injectable Grade	Highest Governed by regulatory agencies	 Ophthalmic surgery Joint Injections Bone grafts Intra-articular injections Carrier for drugs Tissue engineering 	 High Product specs tailored to needs of end user Heightened quality control in US/EU markets Regulatory barriers to change source
	Topical Medical Grade	Moderate Governed by regulatory agencies with less restrictions	Eye dropsTopical wound healingTopical medicationsIntradermal injections	Moderate
	Cosmetic Nutraceuticals	Lowest Limited or no regulatory agency oversight	 Cosmetics, lotions, creams Nutraceuticals, supplements 	Low to No • Commoditized



EXPERTISE IN HA IS THE FOUNDATION FOR EVOLUTION TO A CDMO




HA's role in drugs and devices:

- HA is highly synergistic with new therapies
- HA is a biocompatible, naturally occurring polymer
- Primary commercial use functional ingredient in medical devices
- HA is the excipient that serves as the vehicle for the drug (API)
- HA is a component of the API helping to extend delivery of the drug

CDMO services leverage Lifecore's HA heritage and expertise:

- Over 35 years of experience in development and manufacturing medical devices and drugs
- Handling difficult materials addresses an unmet need within the CDMO market
- Expertise in handling viscous substances lends itself to working with other polymer and drug delivery technologies
- A world class quality and regulatory system with excellent track record with FDA, EMA.






DRIVING LONG-TERM GROWTH AND PROFITABILITY BY MANAGING OUR PIPFLINE



15-20 FDA regulated drug and medical device products in various stages of development

PROJECT LIFE CYCLE



Lifecore can address customers' entire development and commercial lifecycle.



MANAGEMENT: FOCUS ON PROFITABILITY

Albert D. Bolles, Ph.D President & CEO

- Served on Landec's board since May 2014
- Proven track record of visionary leadership and building teams across R&D, technical innovation, quality and supply chain and delivering results through operational excellence, enabling commercial success and profitable growth
- Prior to joining Landec, Dr. Bolles was executive vice president, chief technology and operations officer at ConAgra, served as vice president for PepsiCo Beverages and Foods, (Pepsi, Gatorade, and Tropicana) and Quaker Foods

Brian McLaughlin SVP of Finance and Administration, CFO

- Serves as Landec's CFO responsible for Finance, Accounting and IT
- With the company since 2015 as APIO, now Curation Foods where he originally was hired as the company's Controller
- Prior to joining Landec, Mr. McLaughlin served as CFO for Fresh Express, Driscoll's and Organic Girl and spent nearly 20 years in corporate banking focused on debt restructuring

LANDEC MANAGEMENT TEAM

Albert D. Bolles, Ph.D Landec, President & CEO

Brian McLaughlin Landec, SVP Finance and Administration, CFO

Dawn Kimball Landec, SVP Human Resources, CPO

James G. Hall Lifecore Biomedical, President

Tim Burgess Curation Foods, SVP Supply Chain



LANDEC BOARD OF DIRECTORS FOCUS ON PROFITABILITY

REFRESHED BOARD OF DIRECTORS

BALANCED REPRESENTATION OF BIOMEDICAL & FOOD EXPERTISE

A DIVERSIFIED MIX OF ESTABLISHED LEADERS

Andrew Powell Dr. Albert Bolles Craig Barbarosh Debbie Carosella **Jeffrey Edwards** Katrina Houde **Charles Macaluso Nelson Obus** Tonia Pankopf Joshua Schechter Catherine Sohn Patrick Walsh



NON-GAAP FINANCIAL INFORMATION AND RECONCILIATIONS

The Company has disclosed non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. The non-GAAP Financial measures excludes/includes certain items that are included in the Company's results reported in accordance with GAAP as outlined in the table below. Management believes these non-GAAP financial measures provide useful additional information to investors about trends in the Company's operations and are useful for period-over-period comparisons. The non-GAAP Financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, the non-GAAP financial measures may not be the same as similar measures provided by other companies due to the potential differences in methods of calculation and items being excluded/included. It should be read in conjunction with the Company's consolidated financial statements presented in accordance with GAAP.

